SCHEMBL2660437

SCHEMBL2660437

Cc1ccc2[nH]nc(Nc3nccs3)c2c1C

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ GRM4 Q14833 6/20 0.58
▸ PLA2G7 Q13093 1/20 0.42
▸ MAPK1 P28482 1/20 0.41
▸ NPC1 O15118 4/20 0.40
▸ RAB9A P51151 4/20 0.40
▸ PKM P14618 2/20 0.40
▸ ADRA2A P08913 1/20 0.36
▸ LMNA P02545 1/20 0.36
▸ KMT2A Q03164 1/20 0.36
▸ PPARG P37231 1/20 0.36
▸ NCOR2 Q9Y618 1/20 0.36
▸ ALDH1A1 P00352 2/20 0.33
▸ TDP1 Q9NUW8 1/20 0.33
▸ CSF1R P07333 1/20 0.33
▸ LTK P29376 1/20 0.33
▸ MAPK8 P45983 1/20 0.33
▸ MAPK9 P45984 1/20 0.33
▸ CDK7 P50613 1/20 0.33
▸ CDK9 P50750 1/20 0.33
▸ RPS6KA3 P51812 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25667671 0.76 ADRA2A (0.38) GRM4MAPK1ADRA2A
SCHEMBL6923732 0.73 GRM4 (1.00) GRM4
SCHEMBL2661213 0.73 GRM4 (0.57) GRM4MAPK1ADRA2AALDH1A1TDP1
SCHEMBL2668208 0.70 GRM4 (0.57) GRM4PLA2G7MAPK1
SCHEMBL2660635 0.70 GRM4 (0.58) GRM4MAPK1NPC1RAB9AKMT2A
SCHEMBL2660111 0.70 GRM4 (0.58) GRM4MAPK1LMNAMAPK8
SCHEMBL2660645 0.70 GRM4 (0.58) GRM4MAPK1LMNASMN1; SMN2
SCHEMBL2667982 0.70 GRM4 (0.58) GRM4MAPK1NPC1RAB9ALMNA
SCHEMBL2662181 0.70 GRM4 (0.54) GRM4MAPK1ALDH1A1SMN1; SMN2
SCHEMBL2654720 0.70 GRM4 (0.54) GRM4MAPK1NPC1RAB9APKM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1966152-A2 GLUCOKINASE ACTIVATORS Takeda Pharmaceutical Company Limited (JP) 2008-09-10 — — EP claimed
US-20070244169-A1 GLUCOKINASE ACTIVATORS TAKEDA SAN DIEGO, INC. 2007-10-18 — — US claimed
WO-2007075847-A2 GLUCOKINASE ACTIVATORS TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2007-07-05 — — WO claimed
EP-1966152-A2 GLUCOKINASE ACTIVATORS Takeda Pharmaceutical Company Limited (JP) 2008-09-10 — — EP disclosed
US-20070244169-A1 GLUCOKINASE ACTIVATORS TAKEDA SAN DIEGO, INC. 2007-10-18 — — US disclosed
US-20070244169-A1 GLUCOKINASE ACTIVATORS TAKEDA SAN DIEGO, INC. 2007-10-18 — — US disclosed
US-20070244169-A1 GLUCOKINASE ACTIVATORS TAKEDA SAN DIEGO, INC. 2007-10-18 — — US disclosed
WO-2007075847-A2 GLUCOKINASE ACTIVATORS TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2007-07-05 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070244169-A1 GLUCOKINASE ACTIVATORS GCK, GCKR, GALK1 GRM4 1511/4885PLA2G7 864/4885MAPK1 1276/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback